Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2002 May;26(5):527-31.
doi: 10.1007/s00268-001-0261-7. Epub 2002 Mar 1.

Safe retroperitoneal endoscopic resection of pheochromocytomas

Affiliations

Safe retroperitoneal endoscopic resection of pheochromocytomas

Frits J Berends et al. World J Surg. 2002 May.

Abstract

Although endoscopic adrenalectomy is advocated for small adrenocortical tumors, questions remain about the safety of endoscopic retroperitoneal resection of pheochromocytomas. In this study we evaluated the outcome of retroperitoneal endoscopic adrenalectomy for pheochromocytoma. Between June 1995 and September 1999 we performed 18 retroperitoneal endoscopic adrenalectomies for a pheochromocytoma or paraganglioma. All patients received adequate alpha-adrenergic blockade. The adrenal vein was ligated at the end of the procedure. Operative blood pressure values were recorded and evaluated. Altogether 15 patients (11 women, 4 men; mean age 47.2 years) were operated on for 17 pheochromocytomas and 1 extraadrenal tumor (4 right, 11 left, 3 bilateral). One female patient was operated on at 13 weeks' gestation. Hypertensive episodes at operation were seen in 4 (26.7%) patients, and tachycardia occurred in 5 (33%). Hemodynamic changes could be corrected in all cases using simple measures without morbidity or detrimental effects. The mean operating time was 125 minutes (80-180 minutes), and the conversion rate was 5.6% (1/18). The median hospital stay was 5 days (3-28 days). Morbidity was 20% (3/15). Endoscopic retroperitoneal adrenalectomy for pheochromocytoma is safe and effective, and it is associated with limited morbidity.

PubMed Disclaimer

References

    1. Surg Endosc. 1999 Jan;13(1):86-90 - PubMed
    1. Surg Endosc. 1995 Apr;9(4):431-6 - PubMed
    1. Anaesth Intensive Care. 2000 Feb;28(1):49-53 - PubMed
    1. Ann Surg. 1989 Jun;209(6):774-8 - PubMed
    1. Eur J Surg. 1998 Jan;164(1):23-8 - PubMed

Publication types

LinkOut - more resources